Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells

R Rossi1, M C Zatelli1, A Valentini1, P Cavazzini2, F Fallo3, L del Senno4 and E C degli Uberti1

1Department of Biomedical Sciences and Advanced Therapies – Section of Endocrinology, 2Istituto di Anatomia Patologica, 4Centro di Studi Biochimici delle Patologie del Genoma Umano, Dipartimento di Biochimica e Biologia Molecolare, University of Ferrara, I-44100 Ferrara and 3Division of Endocrinology, University of Padova, Italy

Abstract

Evidence for the expression of the canonic androgen receptor (AR) in human adrenal cortex has not been provided so far. The aim of the present study was to demonstrate the expression of the AR gene in normal and neoplastic adrenocortical human tissues and in the human adrenocortical cancer cell line, NCI-H295, and then to evaluate the effect of dihydrotestosterone (DHT) on human adrenocortical cell growth. An AR cDNA fragment with the expected size of 262 bp was detected by using reverse transcription (RT)-PCR in normal and neoplastic adrenocortical human tissues and in the neoplastic cell line, demonstrating that the gene for AR is indeed expressed in human adrenal cells.

In the human adrenocortical cancer cell line NCI-H295, DHT at physiological concentrations produced a significant reduction in cell proliferation and inhibition of colony formation in soft agar. The inhibitory effect on adrenocortical cell growth was evident after both 24 and 48 h of treatment. The antiandrogens, cyproterone acetate and hydroxyflutamide, were capable of reversing the effects exerted by DHT. The androgen-induced growth inhibitory effect was also detected in primary culture of three non-functioning adrenocortical adenomas.

These findings show that the canonic AR is present in human adrenocortical cells and that androgens may have a role in the adrenal cortex by reducing cell proliferation.


Introduction

Androgens exert a variety of effects upon mammalian tissues by controlling cellular growth and differentiation through a stereospecific high-affinity intracellular receptor and modification of gene expression (Mooradian et al. 1987, Berger & Watson 1989). Whereas androgenic effects associated with differentiation of the male phenotype occur in reproductive tract tissues, anabolic effects occur within non-reproductive tissues such as liver, kidney and muscle (Berger & Watson 1989).

Androgen receptor (AR) has been identified in the adrenal cortex of immature and adult Rhesus monkeys by immunocytochemistry (Hirst et al. 1992) and in adrenocortical tissue of adult rat by immunoblot assay (Bentvelsen et al. 1996). Furthermore, testosterone has been shown to reduce adrenal weight in castrated male rats (Rifka et al. 1978). These data, taken together, suggest that androgens can influence adrenocortical growth and function by a mechanism involving receptor-mediated pathways.

The aim of the present work was to investigate the expression of AR RNA in normal and neoplastic adrenocortical human tissues and in a human adrenocortical cancer cell line, NCI-H295. We also studied the effect of dihydrotestosterone (DHT) on human adrenocortical cell growth, assessing the response of these cells to androgens in terms of morphology and growth properties.

In order to examine whether the action of DHT on human adrenocortical cell growth is mediated by the androgen receptor, we attempted to antagonize it by the antiandrogens, cyproterone acetate and hydroxyflutamide.

Materials and Methods

Collection of adrenocortical tissues

Normal and neoplastic adrenocortical tissues were obtained from female and male patients undergoing surgery for functioning and non-functioning adrenocortical adenomas. No patient was receiving androgenic or steroid
treatment. Eleven benign tumours, including five non-functioning adenosomas, four cortisol- and two aldosterone-producing adenosomas were studied. Normal adrenal tissue was obtained from apparently normal areas of glands from patients undergoing surgery for non-functioning adenoma. After surgery, tissues were immediately frozen in liquid nitrogen under sterile conditions, stored at −80 °C until they underwent RNA extraction, and then pulverized by a tissue dismembrator (Mikro-Dismembrator II, B Braun, Melsungen, Germany). For primary culture experiments, adrenocortical tissue samples were collected under sterile conditions in RPMI 1640 medium (without phenol red, with 2% foetal calf serum; Serva Feinbiochemica, Heidelberg, Germany) and processed within 30 min.

**NCI-H295 cell line culture**

Human NCI-H295 adrenocortical tumour cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were maintained in complete RPMI 1640 medium (without phenol red and with 2% foetal calf serum; FCS; Mascia Brunelli, Milan, Italy), and containing sodium selenite (1 ng/ml, Sigma, St Louis, MO, USA), insulin (5 µg/ml, Novo Nordisk, Princeton, USA), transferrin (5 µg/ml, Sigma), dexamethasone (10−8 M, Sigma), 17β-oestradiol (10−8 M, Sigma), 100 U/ml penicillin and 0·1 mg/ml streptomycin (Mascia Brunelli), 100 µg/ml amphotericine (Squibb, New York, USA) at 37 °C in a humified atmosphere of 5% CO2 and 95% air. To eliminate the influence of steroid hormones in the medium, in the hormone induction experiments, cells were switched to RPMI 1640 medium supplemented with 2% charcoal (1%)–dextran (0·1%)-treated FCS (CDT–FCS), sodium selenite (1 ng/ml), insulin (5 µg/ml), transferrin (5 µg/ml), and antibiotics 3 days before incubation with DHT (Sigma) alone, or with cyproterone acetate or hydroxyflutamide (Schering-Plough, Milan, Italy) alone, or DHT with one of these antiandrogens.

**Growth curve studies**

NCI-H295 cells (5−7 × 10⁴ cells/well) were plated in 24-multi-well plates (Falcon, Lincoln Park, NJ, USA). After overnight growth, cells were incubated in the absence or presence of DHT at concentrations ranging from 10−14 M to 10−8 M in medium without steroids and supplemented with 2% CDT–FCS. Cells were also tested with and without antiandrogens (10−8 M cyproterone acetate and 10−8 M hydroxyflutamide), with and without DHT. After a 24- or 48-h treatment, cells were harvested by trypsinization and counted using a haemocytometer in 12 different experiments. All experiments were carried out in quadruplicate. DHT, cyproterone acetate and hydroxyflutamide were added to the medium in alcohol solution with a final concentration of ethanol <0·1% in both control and hormone-treated cultures. Viability of NCI-H295 cells was determined by tripan blue staining and the number of viable cells was always in the range 85–95%.

**Primary culture of human adrenocortical cells**

After surgical removal of three non-functioning adrenocortical adenomas, the tissue was finely minced with scissors and cells were dispersed by a collagenase digestion (1 mg/ml) in 6 ml complete RPMI 1640 medium as for NCI-H295 cells. The cell suspension was centrifugated at 250 g for 5 min and the cell pellet washed twice and then filtered through a double layer of nylon gauze (300 mesh). Cells were then seeded in monolayer cultures in 24-multiwell plates (Falcon) and grown in complete medium at 37 °C in a humidified atmosphere of 5% CO2–95% air. After 24 h, the medium was replaced with fresh medium without steroids and with CDT–FCS. In this defined medium, treatment with 10−11 M DHT was performed, starting on day 3 of culture, and after 24 h of treatment the cells were harvested by trypsinization and counted using a haemocytometer. Each experiment was done in quadruplicate.

**Isolation of RNA**

Pulverized adrenocortical tissues and cultured carcinoma cells were lysed in guanidium isothiocyanate, and total RNA was purified by phenol–chloroform extraction and isopropanol–ethanol precipitation (RNAzol B solution, Biotech Lab Inc., Houston, TX, USA). To prevent further DNA contamination, RNA was treated for 5 min at 37 °C with RNAse-free DNase and, after 10 min at 70 °C, it was again phenol–chloroform extracted. The amount of RNA was determined by optical density at 260 nm.

**RT-PCR**

Using 1st Strand cDNA Synthesis Kit (Boehringer, Mannheim, Germany), 1 µg total RNA from cultured cells and adrenocortical tissues was reverse-transcribed at 25 °C for 10 min and then at 42 °C for 60 min in a 20-µl solution containing 20 U AMV Reverse Transcriptase, 50 U RNAse inhibitor and 100 pmol AR reverse primer. cDNA product (4 µl RT reaction) was amplified with 1 U *Thermo aquaticus* (Taq) polymerase (Boehringer) and 100 pmol reverse and forward primers in 25 µl reaction mixture containing 200 µmol dNTPs, 50 nmol KCl, 1 mmol MgCl2, 0·01% gelatin and 0·1% Triton X-100. The PCR reaction was performed under mineral oil for 30 cycles of amplification. Each cycle consisted of 94 °C for 60 s, 55 °C for 60 s, 72 °C for 60 s. After the last cycle, samples were incubated for an additional 10 min at 72 °C.
to ensure that the final extension step was complete. The cycling reaction was performed in the DNA thermal cycler from Vioral.

Oligonucleotide primers used for AR cDNA were 5′GTGGATGGCTGAAAATC3′ (sense) and 5′AG ATCATCTCTGTCAAGT3′ (antisense). These are located in exons 7 and 8 of the human AR gene and are expected to amplify an AR cDNA fragment of 262 bp in size. The nucleotide sequence corresponds to the C-terminal sequence of the protein in the hormone binding domain.

After amplification, PCR products were electrophoresed in 2% agarose gel and stained with ethidium bromide.

**Northern blot analysis and probe labelling**

RNA from tissues and cultured adrenocortical carcinoma cells were separated onto denaturing agarose gel, stained with ethidium bromide, transferred to a Gene Screen Plus Filter (NEN, DuPont, Boston, MA, USA) and hybridized essentially as described previously (degli Uberti et al. 1991, Sambrook et al. 1989). Human AR and GAPDH cDNA plasmids were 32P-labelled by the Random Primed DNA labelling kit (Boehringer). Filters were then exposed to X OMAT films at −80°C with Dupont intensifying screens. The levels of AR and GAPDH mRNA in each sample were measured using densitometric analysis of the autoradiographic signals.

**Immunocytochemistry**

In order to visualize the AR protein in adrenocortical carcinoma cell lines, the monoclonal mouse antibody F39.4.1, directed against a fragment of the N-terminal domain of the androgen receptor (aminoacids 301–320) was used, as previously described (Rossi et al. 1996a).

NCI-H295 cells were grown in monolayer (approximately 10^5 cells/well) for 24 h in chamber slides (Nunc Inc., Naperville, IL, USA) in 2% CDT–FCS medium and then incubated with and without 10^{-11} M DHT. After 24 h, cells were washed in saline and, after removal from chamber, were fixed in 3-7% paraformaldehyde for 10 min, rinsed in PBS and transferred to cold methanol and acetone (−20°C) for 3 and 5 min, respectively. After rinsing in PBS, slides were stored at −20°C until required for immunostaining. The antibody was used at 1:200 dilution in PBS. The avidin–biotin detection system was used. All the antisera (normal serum, biotinylated antibody against the primary antibody with 40% normal human serum, and avidin–biotinylated horseradish peroxidase complex) were supplied by commercial kit (Vector Laboratories Inc., Burlingame, CA, USA).

**Assay for anchorage-independent growth**

Agar (Difco) was suspended in water to a final concentration of 2%, autoclaved, and cooled to 50°C. This agar solution (330 µl) was added to twofold concentrated CDT–FCS medium (1 ml) with the hormonal treatment, to make a final volume of 2 ml/well and an agar concentration of 0.6%. Trypsinized NCI-H295 cells were counted and 2 × 10^5 cells were suspended in 50 µl and added to each agar solution (containing hormonal treatment) and immediately poured into 6-multi-well plates. After 10 days of incubation, colonies of more than 100 µm in diameter were randomly scored in triplicate.

**Statistical analysis**

Data are expressed as the mean ± s.e.m. Statistical analysis of the data was performed using the unpaired and paired Student’s t-test and the non parametric Wilcoxon’s test, as appropriate.

**Results**

**AR RNA in human adrenocortical cells and tissues**

Figure 1 shows the presence of AR RNA in human adrenocortical tissues and in the adrenocortical carcinoma cell line NCI-H295. RT-PCR analysis (Fig. 1a), revealed a band with the expected size of 262 bp in normal and adenomatous adrenocortical tissues, and in hyperplastic prostate and in the AR cDNA plasmid, which were included as positive controls. This band was also detected in the adrenocortical carcinoma cell line, NCI-H295, incubated for 24 h in medium supplemented with 2% FCS. Because primers were derived from sequences of exons 7 and 8 of AR cDNA, this band was not the result of genomic contamination. AR RNA transcripts revealed by RT-PCR analysis were also studied by Northern blot analysis. As indicated in Fig. 1b, a signal of approximately 11 kb, as expected for the AR mRNA (Lubahn et al. 1988, Faber et al. 1991), was detected by hybridization with AR cDNA probe in RNA isolated from adrenocortical tissues.

**Detection of AR protein in human adrenocortical carcinoma cells**

Figure 2 shows immunocytochemistry staining for AR protein in NCI-H295 cells grown in the absence and presence of 10^{-11} M DHT, using the monoclonal antibody, F39.4.1. In untreated cells, weak staining was present in the cytoplasm and in the nucleus, with few strongly positive nuclei. In androgen-treated cells, the number of positive nuclei markedly increased. No immunostaining was observed when the primary antibody was replaced by diluent or by non-immune serum.

**Effect of DHT on NCI-H295 cell growth**

Figure 3 shows the effect of androgen on the growth of NCI-H295 cells. DHT significantly (P<0.05) reduced
cell proliferation at concentrations ranging from $10^{-12}$ to $10^{-8}$ M, with a $49.56 \pm 14.8\%$ mean inhibition after 24 h of treatment and with a $51.2 \pm 5.5\%$ mean inhibition after 48 h of treatment. The greatest inhibition of growth was apparent with DHT $10^{-9}$ M ($P<0.01$) after 24 h of treatment. Testosterone reduced NCI-H295 cell proliferation by the same rate and to the same degree of significance as was found for DHT (data not shown).

After 24 h treatment, the antiandrogen, cyproterone acetate, $10^{-8}$ M did not change NCI-H295 cell growth, but was capable of reversing the androgen-induced inhibition of proliferation (Fig. 4A). Comparable results were
obtained using $10^{-8}$ M hydroxyflutamide (Fig. 4B), which was capable of reversing the growth inhibition induced by $10^{-9}$ and $10^{-11}$ M DHT.

**Effect of DHT on growth of human adrenocortical cells in primary culture**

The effect of androgen on human adrenocortical cell proliferation in primary culture was also tested. After 24 h incubation with $10^{-11}$ M DHT, a significant inhibition of cell growth was found in three different experiments, with a mean percentage inhibition of 26-5% compared with control cells ($P<0.05$).

**Anchorage-independent growth inhibition by DHT**

Figure 5 shows the effect of DHT on anchorage-independent growth of NCI-H295 cells. After a 10-day period of growth, control cells formed large colonies in soft
agar whereas, in the presence of $10^{-11}$ M DHT, the growth potential of NCI-H295 cells was consistently reduced. In control samples, 50.3% of colonies showed a diameter greater than 100 µm. In presence of androgen, colonies were less dense and only 21.9% of them reached a size greater than 100 µm ($P<0.01$). Cyproterone acetate again counteracted the DHT-induced reduction of anchorage-independent growth (data not shown).

**Discussion**

In the present study, we have demonstrated the presence of the canonic AR RNA in human adrenocortical tissues, indicating that the gene for AR is, indeed, expressed in human adrenal cortex. AR expression has been confirmed in the human adrenocortical cancer cell line, NCI-H295, in which the AR protein has also been demonstrated by the use of a specific monoclonal antibody, F39.4.1 (Lubahn *et al.* 1988). These observations are in accordance with previously reported findings in other mammalian adrenal tissues. A relatively high level of a specific high-affinity androgen-binding protein (Calandra *et al.* 1978, Rifka *et al.* 1978) has been previously determined by ligand-binding assays in the adrenal gland of rodents. More recently, the presence of AR protein has been demonstrated, by immunocytochemistry and immunoblot, in the adrenal gland of the Rhesus monkey (Hirst *et al.* 1992) and rat (Bentvelsen *et al.* 1996). However, different observations were made by Ruizeveld de Winter *et al.* (1991) who were unable to visualize AR protein in human adrenal specimens using the monoclonal antibody F39.4.1. Such a finding may reflect a level of AR that was too low to be detected immunohistochemically in this tissue.

The increase in nuclear AR positivity induced by androgen treatment is consistent with the nuclear localization of the receptor in the human cells. Similarly, previous results (Husmann *et al.* 1990, Sar *et al.* 1990) have shown that, in rat ventral prostate and epididymis, nuclear immunostaining of AR that is lost after castration rapidly recovers after injection of androgen. These authors have suggested that the androgen-free receptor undergoes a marked increase in immunoreactivity after hormone binding or receptor stabilization, as later proposed by Kemppainen *et al.* (1992). In addition, Jenster *et al.* (1992), studying the relationships between various structural domains and their different functions in the AR protein, showed that, in the absence of ligand, the wild-type AR expressed in COS-1 cells was distributed over nucleus and cytoplasm, and that the addition of hormone directed all ARs to the nucleus.

*Figure 5* Effect of DHT on anchorage-independent growth of NCI-H295 cells. The percentage of colonies greater than 100 µm in diameter was determined after 10 days of growth in soft agar without hormones (control) and in the presence of $10^{-11}$ M DHT (+ DHT) in six independent experiments. *P<0.01* compared with untreated cells. Original magnification, ×100.
Although the action of sex steroid hormones in the adrenal cortex is not entirely clear, it is well known that androgens influence adrenal function, morphology and steroidogenesis. Experimental data have shown that androgen treatment induces an atrophic effect in male rat adrenal cortex, and a trophic action on the zona reticularis in female guinea pigs (Toscano et al. 1990).

To date, the mechanism of action of androgen on human adrenocortical growth and differentiation is not well defined. In agreement with previous data from Rifka et al. (1978), who demonstrated an androgen-induced decrease in rat adrenal weight, our results show that DHT is capable of reducing adrenocortical adenoma and carcinoma cell proliferation. These findings, together with the androgen-induced reduction of colony formation in the NCI-H295 cell line, provide evidence for an inhibitory role of androgen on the growth of the human adrenocortical gland. The inhibitory effect of DHT that we observed with doses ranging from $10^{-12}$ to $10^{-8}$ M was not associated with any induction of a cytotoxic action, as demonstrated by trypan blue staining, and was counteracted by preadministration of both the antiandrogens, cyproterone acetate and hydroxyflutamide. Hydroxyflutamide, in particular, is a pure antiandrogen because, unlike cyproterone acetate, it fails to promote AR dimerization and DNA binding, and lacks any agonistic activity (Wong et al. 1993). As neither of these androgens affected the NCI-H295 proliferation rate, but both blocked DHT-induced growth inhibition, we conclude that androgen, in our model, acts by binding its receptor. These results, together with the finding that human adrenocortical cells express the canonic AR gene at RNA and protein level, are consistent with the concept that androgens may act on the human adrenal gland by a receptor-mediated mechanism.

It is well known that sex steroid receptors have an important role in the control of the proliferation of sex steroid target cells and, in agreement with our results, several studies have shown that physiological doses of synthetic androgens, via interaction with AR, inhibit cell proliferation, colony formation in soft agar, and c-myc RNA levels in the LNCaP prostate cancer cell line (Wolf et al. 1991). Recent data have also demonstrated an AR-mediated androgen-induced inhibition of cell proliferation in the MCF7 cell line transfected with a full human androgen receptor vector (Szelei et al. 1997). In addition, we have recently demonstrated that androgens, via the canonic androgen receptor, reduce cell proliferation of human thyroid follicular cells (Rossi et al. 1996a, b).

DHT may regulate human adrenocortical cell growth via an AR-mediated mechanism, by influencing the expression of genes involved in cell proliferation; however, in the human adrenal gland, the signal transduction pathway from androgen binding to the ultimate cellular response currently remains to be elucidated. Androgen may act on target cells by an autocrine or paracrine mechanism, or may modulate the sensitivity of androgen-responsive cells to stimulatory and inhibitory growth factors. We cannot exclude the possibility that, in the adrenal gland as was observed in the LNCaP cell line, DHT may increase the endogenous level of TGF-β1 (Kim et al. 1996), which can interfere with the stimulatory effect of autocrine growth factors such as epidermal growth factor and basic fibroblast growth factor (Schuumann et al. 1988, Kasser et al. 1995).

In conclusion, our results demonstrate that DHT may induce an inhibitory effect on the growth of the human adrenocortical gland. However, further studies will be required, first to elucidate the exact mechanism of action of DHT on adrenocortical cell growth and, secondly, to investigate a potential role of androgens or their analogues in the treatment of AR-positive adrenocortical carcinomas.

**Acknowledgements**

This work was supported by MURST (40–60%), CNR, Italy No. 97.04455, ACRO, AIRC and by Associazione Ferrarese dell’Ipertensione Arteriosa. We thank Dr Brinkmann (Rotterdam) for the AR antibody.

**References**


Received 19 December 1997
Revised manuscript received 28 April 1998
Accepted 13 July 1998